----
Current ValuationThe current P/E ratio is 91.38, above the reasonable range, cheaper than 16.86% of the time in the past 3 years, and the industry ranks 31/84, the industry Median 21.22.
91.38xP/E
¥253.69Stock price
¥2.78Earnings per share
91.38xP/E
Stock price¥253.69Earnings per share¥2.78
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -35.23x
- Typical range
- -256.19x–-24.77x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
Industry median 21.22x
0255075100
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
Industry median 21.22x
0x40x80x120x160x200x
| Name/Symbol | |||
|---|---|---|---|
688235SHBeOne Medicines | 91.38x | 245.86% | ¥391.26B |
688796SHBiocytogen | 99.32x | -- | ¥36.90B |
301080SZACROBIOSYSTEMS | 84.73x | 38.72% | ¥16.50B |
600201SHJINYU | 96.46x | 147.87% | ¥13.87B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
